( MENAFN - GlobeNewsWire - Nasdaq) PARIS, May 30, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that earlier this month patients in France received the first doses of PYLCLARI ® (INN: Piflufolastat (18F) also known as (18F)-DCFPyL) indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings: Today's news follows earlier announcements by Curium of the first doses for Greece in November 2023, and for 2024 first doses for Italy in February, for the Netherlands in March, and for Germany in May. Benoit Woessmer, PET Europe CEO at Curium commented ,“We are extremely pleased with today's news that PYLCLARI ® is now available to patients with prostate cancer in France. As we continue to redefine the experience of cancer through our trusted legacy in nuclear medicine, the growing availability of PYLCLARI ® in Europe is improving the choice of diagnostic radiopharmaceuticals available to physicians to better diagnose and monitor prostate cancer – ultimately for the benefit of patients with prostate cancer.
” In France, prostate cancer is one of the most common cancers among men with around 60,000 new cases diagnosed nationwide every year. PYLCLARI ® is being produced in France at Curium's facilities in Bordeaux, Lyon, Nancy, Marseille, Paris, and Tours. For more information about PYLCLARI ® : In the U.
.
